BioCentury
ARTICLE | Company News

Takeda names new Millennium president, reports FY12 earnings

May 10, 2013 1:12 AM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Anna Protopapas, EVP and global business development head at the pharma's Takeda Pharmaceutical International Inc. subsidiary, will also become president of Takeda's Millennium Pharmaceuticals Inc. subsidiary. Protopapas will succeed Deborah Dunsire, who is retiring as president and CEO. A Millennium spokesperson said Dunsire's retirement was prompted by Takeda's decision to integrate Millennium's oncology R&D into Takeda's overall research organization, which eliminated the CEO position. The spokesperson said Takeda's oncology R&D hub will stay in Cambridge, Mass., where Millennium is located.

Separately on Thursday, Takeda reported financial earnings for its fiscal year ending March 31, 2013. Net sales for the period were Y1.6 trillion ($16.5 billion), up 3% from Y1.5 trillion ($18.3 billion) in FY11. Takeda lowered its guidance for the fiscal year ending March 31, 2014. The pharma now expects net sales of Y1.59 trillion ($16.9 billion) in FY13, down from Y1.63 trillion ($16.5 billion) previously, and net income of Y95 billion ($961.4 million), down from Y150 billion ($1.5 billion) previously. ...